SCCS Approves Higher Concentration Limits for Nano-Hydroxyapatite

TAKEAWAYS

  • Approved Concentration Limits: The SCCS has concluded that hydroxyapatite (nano) is safe for use at concentrations up to 10% in toothpaste and up to 0.4% in mouthwash.
  • Safety Verdict: The committee determined that the ingredient does not pose a risk of systemic toxicity or local effects when used within these specified limits in oral care products.
  • Mechanism of Action: Nano-hydroxyapatite works by filling microscopic tubules in the enamel, providing a remineralization effect and reducing tooth sensitivity without the use of fluoride.
  • Regulatory Scope: These guidelines specifically apply to “nano” form hydroxyapatite (non-needle-shaped particles) used in consumer cosmetic products within the European market.
  • Industry Impact: This approval allows manufacturers to develop high-potency “clean-label” whitening and repair toothpastes that meet rigorous EU safety standards for consumer protection.
  • Quality Requirements: To comply with SCCS findings, the material must consist of rod-shaped or nearly spherical particles and must not be “needle-shaped,” as the latter carries different safety implications.

 

Nano-hydroxyapatite (INCI: Hydroxyapatite, CAS No. 1306-06-5), a common ingredient used as an abrasive, filler, oral care agent, and skin conditioning agent in cosmetics, has been under regulatory scrutiny in the EU due to its nanoscale form. Historically regulated under the EU Cosmetics Regulation (EC) No. 1223/2009, nano-hydroxyapatite has had strict concentration limits in oral care applications—10% in toothpaste and 0.465% in mouthwash—governed under Annex III, entry 372.

But that’s changing.

On July 1, 2025, the EU’s Scientific Committee on Consumer Safety (SCCS) released its fourth opinion (SCCS/1677/25) on nano-hydroxyapatite, following renewed industry requests for a reassessment. The result: a significant increase in approved usage limits for this ingredient in oral care products.

Why Nano Materials Face Special Scrutiny in the EU

The EU maintains some of the strictest cosmetic regulations globally—especially regarding nanomaterials. Due to their unique particle size and potential for enhanced penetration, nanomaterials used in cosmetic products must undergo safety evaluations and comply with specific labeling and notification rules:

  • Any cosmetic product containing nanomaterials (except colorants, preservatives, or UV filters) must be notified to the European Commission at least 6 months prior to being placed on the market.

  • Nanomaterials must be clearly indicated in the ingredients list with the word “(nano)” following the substance name.

  • When potential safety concerns arise, the Commission may task the SCCS with conducting a comprehensive risk assessment.

Nano-hydroxyapatite has been one such material.Hydroxyapatite

The SCCS’s Previous Opinions: Why Re-evaluation Was Needed

Between 2015 and 2021, the SCCS issued two evaluations on the safety of nano-hydroxyapatite in cosmetic use (SCCS/1566/15 and SCCS/1624/20). At the time, the committee could not confirm a safe concentration or acceptable technical specifications for the needle-like rod-shaped form used in oral care.

This uncertainty limited the allowable concentration of nano-hydroxyapatite in toothpaste and mouthwash and made it subject to further review. The SCCS finally issued a more favorable opinion in March 2023 (SCCS/1648/22), declaring that nano-hydroxyapatite—meeting specific particle specifications—is safe at 10% in toothpaste and 0.465% in mouthwash.

EU Regulation Update: Entry 372 and (EU) 2024/858

Based on the 2023 SCCS opinion, the European Commission updated its regulatory stance through Regulation (EU) 2024/858, officially amending Annex III and defining new use conditions for nano-hydroxyapatite. These include:

  • Toothpaste: maximum concentration of 10%

  • Mouthwash: maximum concentration of 0.465%

  • Only specific particle morphology is allowed (described below)

The transition period for the cosmetics industry is as follows:

  • From February 1, 2025: Products not complying with the new specifications cannot be placed on the EU market.

  • From November 1, 2025: Non-compliant products must be removed from the EU market.

Industry Response and Request for Reassessment

Following the adoption of (EU) 2024/858, several stakeholders submitted requests to the European Commission to reassess whether nano-hydroxyapatite could be used at higher concentrations—particularly in toothpaste, where performance benefits are concentration-dependent.

As a result, the SCCS conducted another full safety review and released SCCS/1677/25 in July 2025.

Key Findings from SCCS/1677/25: Safety at Higher Concentrations Confirmed

The SCCS has now concluded that nano-hydroxyapatite—when formulated according to strict particle specifications—is safe to use at:

  • 29.5% in toothpaste

  • 10% in mouthwash

These significantly expanded limits offer greater formulation flexibility and efficacy potential for oral care brands targeting enamel remineralization, anti-sensitivity, and whitening benefits.

Important Safety Justifications

According to the SCCS, the following safety considerations support the revised concentration limits:

  • Negligible mucosal uptake: Nano-hydroxyapatite particles are not significantly absorbed through oral mucosa.

  • Continuous epithelial shedding: Oral epithelial cells that may have absorbed particles naturally slough off over time.

  • Gastrointestinal dissolution: Any nano-hydroxyapatite inadvertently swallowed is rapidly dissolved in stomach acid, minimizing systemic exposure and rendering nanoparticle-related risks negligible.

Strict Technical Specifications Still Apply

To ensure safety, only nano-hydroxyapatite that meets the following criteria is permitted under the new guidance:

  1. Particle shape and distribution:

    • Must consist entirely of rod-shaped particles

    • At least 87% of particles (by number) must have an aspect ratio ≤ 3

    • Remaining particles may not exceed an aspect ratio of 9

  2. Surface properties:

    • No surface coating or surface modification allowed

  3. Particle size:

    • Maximum length of particles is 122 ± 43 nanometers

Important: This safety opinion does not apply to any nano-hydroxyapatite material containing needle-shaped particles or with unapproved morphology.

Implications for Oral Care Brands and Manufacturers

This update represents a major opportunity for formulators of next-generation oral care products. The higher concentration threshold for nano-hydroxyapatite:

  • Enables more potent remineralization and whitening effects

  • Allows brands to differentiate with premium positioning

  • Makes way for innovation in sensitivity relief and enamel-strengthening formulations

However, it also comes with regulatory responsibility. Only nano-hydroxyapatite that meets strict EU-defined morphology and purity standards is permitted—documentation and supplier verification will be critical to ensure compliance.Calcium Hydroxyapatite

What’s Next

Companies intending to use nano-hydroxyapatite above previous limits must:

  • Ensure particle specifications are aligned with SCCS/1677/25

  • Review their formulation documentation

  • Update product notifications under the EU CPNP (Cosmetic Products Notification Portal)

  • Monitor the implementation of market deadlines (February 1 and November 1, 2025)

The increased limit gives oral care developers a wider toolbox, but only if they meet the EU’s exacting safety criteria.

Final Thoughts

The SCCS’s revised safety opinion on nano-hydroxyapatite marks a pivotal moment for oral care innovation within the EU. While it opens the door to stronger and more effective formulations, compliance with narrow technical specifications remains essential.

For businesses in the oral care industry, now is the time to revisit your nano-hydroxyapatite sourcing, validate your particle morphology, and explore how these new limits can help you create better-performing products that stay within the bounds of EU safety regulations.

Stay Compliant. Stay Competitive.

Need support in reformulating or verifying ingredient compliance for the EU market? Partner with regulatory experts and ingredient suppliers familiar with SCCS guidelines to future-proof your oral care product line.

Awesome! Share to:

Written-By-Human-Not-By-AI-Badge-white

|   Written by:

Manufacture My Own Branded Products

Make Cinoll your private label product manufacturer. We own FDA, GMP and ISO certificates as your reliable partner.

More Cinoll Articles